Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
6.00
-0.15 (-2.44%)
Jul 23, 2026, 12:24 PM EDT - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Entrada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $18.75. The average 1-year stock price forecast is 212.50% higher than the current stock price, while the lowest is $10 (+66.67%) and the highest is $25 (+316.67%).
Price Target: $18.75 (+212.50%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 5, 2026.
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +183.33% | Jun 5, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 | Buy | Reiterates | $23 | +283.33% | Jun 3, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $6.64 → $10 | Buy | Reiterates | $6.64 → $10 | +66.67% | Jun 3, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Financial Forecast
Revenue This Year
14.99M
from 25.42M
Decreased by -41.04%
Revenue Next Year
29.81M
from 14.99M
Increased by 98.87%
EPS This Year
-3.79
from -3.47
EPS Next Year
-3.26
from -3.79
EPS and Forward PE are based on non-GAAP adjusted numbers.